Skip to main content
    S

    Scholar Rock Holding Corp (SRRK)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $44.54
    +1.33 (+3.09%)

    Market Cap: $5.27B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Scholar Rock Holding Corp (SRRK) Earnings: Report Dates and Results

    Updated Nov 10, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    Scholar Rock Holding (SRRK) is expected to report earnings on Mar 1, 2027. In the quarter ended Sep 30, 2026, Scholar Rock Holding reported EPS of -$0.81, above the -$0.87 estimate. It beat the EPS estimate in 4 of the last 8 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    41%(14/34)
    Avg Surprise
    -8.09%
    Streak
    1 Q

    Upcoming Estimates

    Reports Mar 1, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus-$0.74
    Range-$0.98 - $0.87
    20 analysts
    Revenue Consensus
    $4.34M
    Range$1.09M - $9.55M
    17 analysts
    Reports May 5, 2027 (est.)Period ending Mar 31, 2027
    EPS Consensus-$0.81
    Range-$0.98 - -$0.71
    3 analysts
    EPS Revisions
    1
    1
    30d
    EPS Estimate DriftChange to current
    90d ago-$0.71-13.9%
    60d ago-$0.71-13.9%
    30d ago-$0.72-11.2%
    7d ago-$0.76-6.6%
    Current-$0.81
    Revenue Consensus
    $11.99M
    Range$4.20M - $16.00M
    4 analysts

    Next Report

    SRRK has an expected report date of Mar 1, 2027.

    SRRK Earnings Call

    The latest SRRK earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    Earnings History

    Of the 34 quarters below that had an estimate, SRRK beat 14, missed 18 and matched 2. The widest gap in the table came in the quarter ended Mar 31, 2018, when EPS landed 104.00% below the estimate.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026-$0.81-$0.87-$0.94 - -$0.73+6.90%BeatN/A121 up, 0 downNov 10, 2026$570000
    Jun 30, 2026-$0.84-$0.84-$0.94 - -$0.770.00%In lineN/A113 up, 3 downAug 6, 2026N/A
    Mar 31, 2026-$0.83-$0.78-$0.91 - -$0.62-6.41%MissN/A131 up, 0 downMay 7, 2026N/A
    Dec 31, 2025-$0.88-$0.90-$1.07 - -$0.57+2.04%BeatN/A112 up, 7 downMar 3, 2026N/A
    Sep 30, 2025-$0.90-$0.84-$1.00 - -$0.57-7.14%MissN/A9N/ANov 14, 2025N/A
    Jun 30, 2025-$0.98-$0.67-$0.73 - -$0.57-46.27%MissN/A50 up, 0 downAug 6, 2025N/A
    Mar 31, 2025-$0.67-$0.71-$0.93 - -$0.54+5.63%BeatN/A40 up, 3 downMay 14, 2025N/A
    Dec 31, 2024-$0.61-$0.63-$0.67 - -$0.58+2.99%BeatN/A51 up, 4 downFeb 27, 2025N/A
    Sep 30, 2024-$0.66-$0.59-$0.65 - -$0.54-11.86%MissN/A90 up, 0 downNov 12, 2024N/A
    Jun 30, 2024-$0.60-$0.59-$0.72 - -$0.57-1.69%MissN/A90 up, 0 downAug 8, 2024N/A
    Mar 31, 2024-$0.59-$0.51-$0.60 - -$0.45-15.69%MissN/A90 up, 0 downMay 7, 2024N/A
    Dec 31, 2023-$0.50-$0.49-$0.54 - -$0.45-2.04%MissN/A80 up, 0 downMar 19, 2024$11.66M
    Sep 30, 2023-$0.53-$0.51-$0.68 - -$0.46-3.92%MissN/A81 up, 0 downNov 7, 2023N/A
    Jun 30, 2023-$0.47-$0.55-$0.79 - -$0.48+14.55%BeatN/A70 up, 0 downAug 9, 2023N/A
    Mar 31, 2023-$0.49-$0.52-$0.81 - -$0.48+5.77%BeatN/A60 up, 0 downMay 9, 2023N/A
    Dec 31, 2022-$0.46-$0.57-$0.77 - -$0.49+19.30%BeatN/A80 up, 0 downMar 7, 2023$33.19M
    Sep 30, 2022-$0.55-$0.64-$0.87 - -$0.43+14.06%BeatN/A80 up, 0 downNov 14, 2022N/A
    Jun 30, 2022-$1.06-$1.01N/A-4.95%MissN/AN/A2 up, 0 downAug 8, 2022N/A
    Mar 31, 2022-$0.21-$0.62-$1.16 - -$0.16+66.13%BeatN/A70 up, 0 downMay 16, 2022$33.19M
    Dec 31, 2021-$0.97-$1.00-$1.19 - -$0.92+3.00%BeatN/A5N/AMar 7, 2022$4.05M
    Sep 30, 2021-$1.02-$0.76N/A-34.21%MissN/A5N/ANov 9, 2021$5.46M
    Jun 30, 2021-$0.84-$0.73-$0.86 - -$0.66-15.07%MissN/A5N/AAug 10, 2021$4.59M
    Mar 31, 2021-$0.76-$0.65-$0.78 - -$0.62-16.92%MissN/A5N/AMay 13, 2021$4.71M
    Dec 31, 2020-$0.79-$0.63-$0.74 - -$0.57-25.40%MissN/A6N/AMar 9, 2021$3.44M
    Sep 30, 2020-$0.79-$0.50-$0.63 - -$0.48-58.00%MissN/A4N/ANov 9, 2020$3.04M
    Jun 30, 2020-$0.65-$0.46N/A-41.30%MissN/A5N/AAug 7, 2020$3.90M
    Mar 31, 2020-$0.58-$0.02-$0.46 - $0.30N/AN/AN/A5N/AMay 7, 2020$5.03M
    Dec 31, 2019-$0.39-$0.53-$0.65 - -$0.50+26.42%BeatN/A4N/AMar 12, 2020$7.57M
    Sep 30, 2019-$0.55-$0.41-$0.52 - $0.02-34.15%MissN/A4N/ANov 12, 2019$4.77M
    Jun 30, 2019-$0.48-$0.31N/A-54.84%MissN/A4N/AAug 14, 2019$5.04M
    Mar 31, 2019-$0.42-$0.50-$0.61 - -$0.38+16.00%BeatN/A4N/AMay 14, 2019$3.11M
    Dec 31, 2018-$0.43-$0.45N/A+4.44%BeatN/A4N/AMar 18, 2019N/A
    Sep 30, 2018-$0.44-$0.56-$1.17 - -$0.44+21.43%BeatN/A4N/ANov 8, 2018N/A
    Jun 30, 2018-$0.58-$0.58-$1.39 - -$0.430.00%In lineN/A4N/AAug 8, 2018N/A
    Mar 31, 2018-$1.02-$0.50N/A-104.00%MissN/A1N/AMay 24, 2018N/A
    Mar 31, 2017-$0.19N/AN/AN/AN/AN/AN/AN/AJun 29, 2017N/A
    Last 36 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was -$3.43, after -$2.46 the year before. It was -$2.66 for the year ended Dec 31, 2018, the oldest of the 8 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025-$3.43N/A
    Dec 31, 2024-$2.46N/A
    Dec 31, 2023-$1.99N/A
    Dec 31, 2022-$2.28N/A
    Dec 31, 2021-$3.59N/A
    Dec 31, 2020-$2.81N/A
    Dec 31, 2019-$1.84N/A
    Dec 31, 2018-$2.66N/A

    Earnings Calls

    The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 9,300 words across 17 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q3Sep 30, 20269,25917
    2026Q2Jun 30, 20267,03518
    2026Q1Mar 31, 20268,30117
    2025Q4Dec 31, 20257,75919
    2025Q3Sep 30, 20257,06514
    2025Q2Jun 30, 20256,14013
    2025Q1Mar 31, 20256,28716
    2024Q4Dec 31, 20246,2058

    2026Q3 Earnings Call

    Opening remarks

    Laura Ekas Vice President, Investor Relations Good morning. I'm Laura Ekas, Vice President, Investor Relations at Scholar Rock. With me today are David Hallal, Chairman and Chief Executive Officer; Keith Woods, Chief Operating Officer; Akshay Vaishnaw, President of R&D; and Vikas Sinha, Chief Financial Officer. During today's call, David will provide introductory remarks and a business overview. Keith will discuss the U.S. launch of ISEMBYLD and global commercial readiness. Akshay will review our regulatory and R&D progress, and Vikas will provide a financial update. We will then open the call for questions. Before we begin, I'd like to remind you that during this call, we will be making various statements about Scholar Rock's expectations, plans and prospects that constitute forward-looking statements for the purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Any forward-looking statements represent our views only as of today and should not be relied upon as representing our views as of any future date. I encourage you to go to the Investors and Media section of our website for our most up-to-date SEC statements and filings. With that, I'd like to turn the call over to David. David?

    David Hallal Chairman and Chief Executive Officer Thank you, Laura, and good morning. Thanks to everyone for joining our third quarter earnings call. Today, Scholar Rock is operating from a position of great strength, and we are executing with focus, discipline and urgency. In mid-September, we received FDA approval well ahead of our PDUFA date for ISEMBYLD, the world's first and only muscle-targeted therapy for children and adults living with SMA. And following approval, we immediately commenced our U.S. launch. In early October, we resubmitted our apitegromab MAA in Europe for the treatment of children and adults with SMA. The application, which now includes our alternate fill/finish facility, has been validated, and we expect a CHMP opinion in the first half of 2027. In early November, we submitted our apitegromab JNDA in Japan, 2 months ahead of our guidance. The application was accepted under priority review and, pending approval, we anticipate a launch in Japan near year-end 2027. In Q3, we also commenced dosing in our Phase II FORGE study, evaluating apitegromab in people living with FSHD. And finally, this morning, we announced we have entered into a definitive agreement to monetize our priority review voucher for $205 million, which will further strengthen our financial position to fund our ambitious global commercial and R&D growth initiatives. With this, let me turn to our U.S. approval and launch of ISEMBYLD. ISEMBYLD is a highly innovative myostatin inhibitor and the world's first and only muscle-targeted therapy approved for patients with SMA.

    Frequently Asked Questions About SRRK

    When is Scholar Rock Holding's next earnings date?

    Scholar Rock Holding's next earnings report is expected for Mar 1, 2027.

    Did SRRK beat earnings estimates last quarter?

    Yes. Scholar Rock Holding reported EPS of -$0.81 for the quarter ended Sep 30, 2026, above the -$0.87 estimate, a 6.90% surprise.

    What EPS do analysts expect from SRRK next quarter?

    The consensus EPS estimate for Scholar Rock Holding for the quarter ending Dec 31, 2026 is -$0.74 from 20 analysts, with estimates from -$0.98 to $0.87.

    How often does SRRK beat earnings estimates?

    Scholar Rock Holding beat the EPS estimate in 4 of the last 8 quarters, with an average surprise of -5.28%.